期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨联合柔红霉素对HL-60细胞增殖及PTEN基因表达的影响 被引量：3

原文传递
导出
摘要 人第10号染色体缺失的磷酸酶及张力蛋白同源基因（Phosphatase and tensin homology deleted on chromosome tengene，PTEN）是近年发现的定位于染色体10q23．3的一个重要抑癌基因，其编码的蛋白具有脂质磷酸酶和蛋白磷酸酶活性，发挥双重肿瘤抑制功能。地西他滨（DAC）是目前研究较多的甲基化抑制剂，可逆转CpG岛甲基化，使多种因甲基化而失活的抑癌基因重新表达，抑制肿瘤细胞生长而达到治疗肿瘤的目的。
作者 罗静 马梁明 侯翠芳 张丽 鹿育晋 张华屏
机构地区 山西医科大学第二医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第6期486-488,共3页 Chinese Journal of Hematology
关键词 HL-60细胞增殖 地西他滨 基因表达 PTEN 柔红霉素 CPG岛甲基化 抑制肿瘤细胞生长 肿瘤抑制功能
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Myers MP, Stolarov JP, Eng C, et al. PTEN, the tumor suppres- sor from human chromosome 10q23, is adual specificity phospha- tase. Proc Natl Acad Sci U S A, 1997, 94: 9052-9057.
  • 2Jabbour E, Issa JP, Garcia-Manero G, et al. Evolution of decit- abine development : accomplishments, ongoing investigations, andfuture strategies. Cancer, 2008,112:2341-2351.
  • 3杨晶,杜雯,贺艳丽,刘隽,郑金娥,黄士昂.B-ALL患者PTEN表达及其启动子甲基化状态研究[J].内科急危重症杂志,2007,13(4):141-143. 被引量：4
  • 4Li P,Li C,Zhao X,et al. 1727( KIP1 ) stabilization and G1 arrest by 1,25-dihy- droxyvitamin D (3) in ovarian cancercells mediated through down-regulation of cyclin E/cyc-lin-dependent kinase 2 and Skpl-Cullin-F-box protein /Skp2 ubiqnitin ligase. J Biol Chem ,2004,279 : 25260-25267.
  • 5Martin V, Valencia A, Agirre X, et al. Epigenetic regulation of the non- canonical Wnt path wayin acute myeloid leukemia. Canc- er Science, 2010,101: 425-432.
  • 6Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyro- sine phosphatase SHP1 gene by aberrant methylation in leukemias/ lymphomas. Cancer Res, 2002,62 : 6390-6394.
  • 7EI-Osta A. The rise and fall of genomic methylation in cancer. Leu- kemia, 2004, 18:233-237.
  • 8Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low dose prolonged exposure schedules of the hypomethylating gent 5 aza 2'deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004, 103 : 1635-1640.
  • 9de Lima M, Ravandi F, Shahjahan M, et al. Long-tern1 follow-up of a phase I study of high-dose decitabine, busulfan, and cyclo- phosphamide plus allogeneic transplantation for the trealment of pa- tients with leukemias. Cancer,2003 ,97 :1242 -1247.
  • 10Schwartsmann G, Fernandes MS, Schaan MD, et al. Decitabine (5-Aza-2'-deoxy-cytidine, DAC ) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia, 1997,11 : S28-S31.

二级参考文献41

  • 1沈权,陈泽,刘旭萍,邢海燕,王敏,王建祥.抑癌基因PTEN mRNA在白血病细胞中的表达及意义[J].中华血液学杂志,2005,26(8):493-496. 被引量：20
  • 2Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer, 2001, 91:22-26.
  • 3Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res, 1997, 57:4736-4738.
  • 4Idoate MA, Sofia E, Lozano MD, et al. PTEN protein expression correlates with PTEN gene molecular changes but not with VEGF expression in astrocytomas. Diagn Mol Pathol, 2003, 12: 160- 165.
  • 5Chung MJ, Jung SH, Lee B J, et al. Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int, 2004, 54:10-15.
  • 6Koenig A, Bianco SR, Fosmire S, et al . Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol, 2002, 39: 458-472.
  • 7Tanaka Y, Gavrielides MV, Mitsuuchi Y, et al. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem, 2003,278 : 33753-33762.
  • 8Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 1998, 280: 1614-1617.
  • 9Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogeni.c effects. J Biol Chem, 2002, 277 : 10760-10766.
  • 10Abe T, Terada K, Wakimoto H, et al. PTEN decreases in vivo vascularization of experimental gliomas inspite of proangiogenic stimuli. Cancer Res, 2003, 63 : 2300-2305.

共引文献28

同被引文献32

  • 1杨平,曹杰,王辉,孙政,李旺林,谭明华.奥沙利铂诱导结肠癌细胞株SW480凋亡过程中caspase-8的活化[J].广东医学,2007,28(3):345-348. 被引量：11
  • 2杨力,徐瑞容,黄红铭,丁润生,姜胜华.地西他滨对MDS细胞株SKM-1的作用研究[J].交通医学,2007,21(1):34-35. 被引量：7
  • 3Malik P,Cashen AF. Decitabine in the treatment of acute myeloid leukemia in elderly patients [ J ]. Cancer Manag Res,2014,6:53 - 61.
  • 4Zagonel V, Lo RG, Marotta G, et al. 5-Aza-2'- deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes [ J ]. Leukemia, 1993,7:30 - 35.
  • 5Kantarjian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes [ J ]. Cancer,2006,106 (8) : 1794 - 1803.
  • 6Ltibbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase m study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group [ J ]. J Clin Oneo1,2011,29 ( 15 ) : 1987 - 1996.
  • 7Kantarjian H, Oki Y, Garcia-Manero G,et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastie syndrome and chronic myelomonocytic leukemia [ J ]. Blood, 2007,109 ( 1 ) : 52 -57.
  • 8Steensma DP, Baer MR, Slack JL, et al. Muhicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes:the alternative dosing for outpatient treatment (ADOPT) trial[ J]. J Clin Oncol, 2009,27 ( 23 ) : 3842 - 3848.
  • 9Lee JH,Jang JH,Park J, et al. A prospective muhicenter observational study of deeitabine treatment in Korean patients with myelodysplastic syndrome [ J ]. Haematolo- gica,2011,96(10) :1441 - 1447.
  • 10Garcia-Manero G, Jabbour E, Borthakur G, et al. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes [ J ]. J Clin Oncol, 2013,31 ( 20 ) : 2548 - 2553.

引证文献3

二级引证文献6

中华血液学杂志
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部